An ovarian neoplasm composed of LUTEAL CELLS derived from luteinized GRANULOSA CELLS and THECA CELLS. Luteomas respond to GONADOTROPINS, and vary in their hormone production (PROGESTERONE; ESTROGENS; or ANDROGENS). During PREGNANCY, a transient type of luteoma may develop due to an exaggerated LUTEINIZATION of the OVARY.
Neoplasms derived from the primitive sex cord or gonadal stromal cells of the embryonic GONADS. They are classified by their presumed histogenesis and differentiation. From the sex cord, there are SERTOLI CELL TUMOR and GRANULOSA CELL TUMOR; from the gonadal stroma, LEYDIG CELL TUMOR and THECOMA. These tumors may be identified in either the OVARY or the TESTIS.
The co-occurrence of pregnancy and NEOPLASMS. The neoplastic disease may precede or follow FERTILIZATION.

Luteoma of pregnancy: sonographic findings in two cases. (1/10)

Luteoma of pregnancy is a rare nonneoplastic tumor-like mass of the ovary that emerges during pregnancy and regresses spontaneously after delivery. It is usually asymptomatic and is found incidentally during a cesarean section or postpartum tubal ligation. However, luteomas can be hormonally active, with production of androgens resulting in maternal and fetal hirsutism and virilization. Less than 200 cases have been described in the literature, and none in radiologic journals. Recognition of this entity is important so that unnecessary oophorectomy, with concomitant risk to both the patient and the fetus, is avoided. In this report, we describe two cases of luteoma of pregnancy. The first case documents sequential ultrasonographic demonstration of a presumed luteoma of pregnancy in a patient who was seen with hirsutism during a second trimester pregnancy. The luteoma, serum androgen levels, and patient's condition improved after delivery. This case is unique in that although the mass significantly decreased in size post partum, it continued to be visualized 14 months post partum. The second case illustrates the pronounced cystic appearance that these classically described solid lesions can demonstrate because of extensive necrosis.  (+info)

Prenatal diagnosis of female pseudohermaphroditism associated with bilateral luteoma of pregnancy: case report. (2/10)

Female pseudohermaphroditism associated with luteoma of pregnancy (LP) is a rare condition characterized by varying degrees of masculinization of a female fetus. We describe a case, diagnosed at 13 weeks gestation. Transvaginal ultrasound at 5 weeks of gestation revealed a normal intrauterine gestational sac and an enlarged maternal right ovary. Re-examination at 13 weeks showed a fetus with male external genitalia. Cytogenetic investigation on amniotic fluid revealed a normal female karyotype 46,XX. Follow-up sonography confirmed the previous assignment of male external genitalia and a second amniocentesis was negative for the SRY gene. High levels of androgens were found in the maternal blood. A diagnosis of female pseudohermaphroditism associated with bilateral LP was made. A healthy girl was born by Caesarean section with complete masculinization of external genitalia (Prader V). Histology confirmed a bilateral LP. To the best of our knowledge this represents the first case of prenatal diagnosis of female pseudohermaphroditism associated with LP and demonstrates the feasibility of diagnosis by sonography from 13 weeks gestation. This is also the first case described of Prader V masculinization associated with LP.  (+info)

Development of an experimental ovarian tumor: immunocytochemical analysis. (3/10)

OBJECTIVE: The aim of the present work was to study whether immunocytochemical parameters present in the normal ovary were altered after tumor development under high gonadotropin levels. METHODS: Ovarian tumors (luteoma): castrated female rats had an ovary grafted into the spleen; tumors were left to develop for 1, 2, 3 or 7 months. The presence of apoptotic cells (TUNEL method) and the expression of proliferating cell nuclear antigen (PCNA), gap junction protein (Cx43), steroidogenic acute regulatory protein (StAR), aromatase and synaptosome-associated protein of 25 kDa (SNAP-25) were determined by immunocytochemistry. Some of these findings were confirmed by RT-PCR (Cx43, StAR, SNAP-25). Inhibin subunit mRNAs were investigated by Northern blot. RESULTS: PCNA staining of tumors was mainly found in granulosa cells of transforming follicles and was absent from luteinized follicles. A nearly complete absence of apoptosis was observed. Cx43 was mainly found in follicles, while it was very weakly expressed or absent in luteinized follicles. StAR protein expression, indicating active steroidogenesis, was demonstrated only in luteinized follicles and in thecal cells, but was absent from granulosa cells. Aromatase immunoreactivity was very intense in granulosa and also present in luteal cells. Membrane-associated and cytoplasmic SNAP-25 immunostaining was determined in patches of endocrine cells in the follicles, as well as in the luteinized follicles. The expression of mRNAs for Cx43, StAR and SNAP-25 (RT-PCR) and inhibin subunits (Northern blots) were confirmed in 1-, 3- and 7-month-old tumors. CONCLUSIONS: These results indicated that luteoma most likely develop from unruptured follicles by hypertrophy and proliferation of follicular cells. Circulating gonadotropins seem to play a fundamental role in maintaining the expression of proteins typically expressed in normal ovary, while avoiding apoptosis in this tissue.  (+info)

MR imaging of pregnancy luteoma: a case report and correlation with the clinical features. (4/10)

We report here on a 26-year-old pregnant female who developed hirsutism and virilization during her third trimester along with a significantly elevated serum testosterone level. Abdominal US and MR imaging studies were performed, and they showed unique imaging features that may suggest the diagnosis of pregnancy luteoma in the clinical context. After the delivery, the serum testosterone level continued to decrease, and it returned to normal three weeks postpartum. The follow-up imaging findings were closely correlated with the clinical presentation.  (+info)

Pregnancy luteoma presenting as ovarian torsion with rupture and intra-abdominal bleeding. (5/10)

We report a case of pregnancy luteoma, which had undergone torsion in a 33-year-old Indian woman, who presented with severe abdominal pain and decreasing haemoglobin levels at 33 weeks gestation. Ultrasonography showed a right adnexal mass, probably ovarian in origin, with suspicious intratumoral bleed. The pain was treated symptomatically, and the symptoms improved. A successful induction of labour was then performed at 36 weeks gestation. The pain recurred almost immediately after the delivery, and she experienced another intra-abdominal bleed. A diagnostic laparotomy and a right salpingo-oophorectomy were performed, and the diagnosis of luteoma was made based on histology. We discuss the clinical presentation of this unusual tumour, though often asymptomatic, can rarely present with severe abdominal pain from complications like torsion with rupture, leading to massive intra-abdominal bleeding. We also discuss the possible radiological investigations which can be done during pregnancy.  (+info)

Hyperandrogenic states in pregnancy. (6/10)

Hyperandrogenic states in pregnancy are almost always the result of a condition that arises during pregnancy. The onset of virilization symptoms is often very fast. The mother is protected against hyperandrogenism by a high level of SHBG, by placental aromatase and a high level of progesterone. The fetus is protected from the mother's hyperandrogenism partly by the placental aromatase, that transforms the androgens into estrogens, and partly by SHGB. Nevertheless there is a significant risk of virilization of the female fetus if the mother's hyperandrogenic state is serious. The most frequent cause of hyperandrogenic states during pregnancy are pregnancy luteoma and hyperreactio luteinalis. Hormonal production is evident in a third of all luteomas, which corresponds to virilization in 25-35 % of mothers with luteoma. The female fetus is afflicted with virilization with two thirds of virilized mothers. Hyperreactio luteinalis is created in connection with a high level of hCG, e.g. during multi-fetus pregnancies. This condition most frequently arises in the third trimester, virilization of the mother occurs in a third of cases. Virilization of the fetus has not yet been described. The most serious cause of hyperandrogenism is represented by ovarian tumors, which are fortunately rare.  (+info)

Miscellaneous tumour-like lesions of the ovary: cross-sectional imaging review. (7/10)

 (+info)

Immunohistochemical characterization of nonhuman primate ovarian sex cord-stromal tumors. (8/10)

 (+info)

A luteoma is a benign ovarian tumor that is composed of luteinized cells, which are typically found in the corpus luteum of the ovary. The corpus luteum is a temporary endocrine structure that forms during the menstrual cycle and produces progesterone to support pregnancy.

Luteomas are rare tumors that usually occur in women of reproductive age, particularly those who have used fertility drugs or who have had prolonged exposure to high levels of estrogen. They can be asymptomatic or may cause symptoms such as abdominal pain, bloating, and menstrual irregularities.

Luteomas are typically diagnosed through imaging studies such as ultrasound or CT scan, and the diagnosis is confirmed through biopsy or surgical removal of the tumor. Treatment usually involves surgical removal of the tumor, and the prognosis is generally good, with a low risk of recurrence. However, luteomas can produce high levels of hormones that may cause virilization or other endocrine abnormalities, so follow-up care is important to monitor for any potential complications.

Sex cord-gonadal stromal tumors are a type of rare cancer that develops in the cells of the ovaries or testicles that produce hormones and help to form ova or sperm. These tumors can be benign (noncancerous) or malignant (cancerous), and they can occur in both males and females, although they are more common in females.

There are several subtypes of sex cord-gonadal stromal tumors, including granulosa cell tumors, thecomas, fibromas, Sertoli cell tumors, Leydig cell tumors, and gonadoblastomas. The symptoms and treatment options for these tumors depend on several factors, including the type and stage of the tumor, the patient's age and overall health, and whether the tumor is producing hormones.

Common symptoms of sex cord-gonadal stromal tumors may include abdominal pain or swelling, bloating, irregular menstrual periods, vaginal bleeding, or a feeling of fullness in the abdomen. In some cases, these tumors may produce hormones that can cause additional symptoms, such as breast tenderness, acne, or voice deepening.

Treatment for sex cord-gonadal stromal tumors typically involves surgery to remove the tumor and any affected tissue. Depending on the stage and type of the tumor, additional treatments such as chemotherapy or radiation therapy may also be recommended. Regular follow-up care is important to monitor for recurrence and manage any long-term effects of treatment.

Neoplastic pregnancy complications refer to the abnormal growth of cells (neoplasia) that can occur during pregnancy. These growths can be benign or malignant and can arise from any type of tissue in the body. However, when they occur in pregnant women, they can pose unique challenges due to the potential effects on the developing fetus and the changes in the mother's body.

Some common neoplastic pregnancy complications include:

1. Gestational trophoblastic disease (GTD): This is a group of rare tumors that occur in the uterus during pregnancy. GTD can range from benign conditions like hydatidiform mole to malignant forms like choriocarcinoma.
2. Breast cancer: Pregnancy-associated breast cancer (PABC) is a type of breast cancer that occurs during pregnancy or within one year after delivery. It can be aggressive and challenging to diagnose due to the changes in the breast tissue during pregnancy.
3. Cervical cancer: Cervical cancer can occur during pregnancy, and its management depends on the stage of the disease and the gestational age. In some cases, treatment may need to be delayed until after delivery.
4. Lung cancer: Pregnancy does not increase the risk of lung cancer, but it can make diagnosis and treatment more challenging.
5. Melanoma: Melanoma is the most common malignant skin cancer during pregnancy. It can spread quickly and requires prompt treatment.

The management of neoplastic pregnancy complications depends on several factors, including the type and stage of the tumor, gestational age, and the patient's wishes. In some cases, surgery, chemotherapy, or radiation therapy may be necessary. However, these treatments can have potential risks to the developing fetus, so a multidisciplinary team of healthcare providers is often involved in the care of pregnant women with neoplastic complications.

Women who have already had a luteoma during a previous pregnancy have a higher high risk of having another luteoma. In this ... A luteoma is a tumor that occurs in the ovaries during pregnancy. It is associated with an increase of sex hormones, primarily ... If the fetus is female then the high levels of testosterone in the umbilical cord could be an indicator that a luteoma is ... This occurs because of the release of testosterone by the luteoma. Testosterone is a sex hormone most abundant in men although ...
Other conditions include: Ovarian cancer Luteoma Hypogonadism Hyperthecosis "Ovarian Disorders". medlineplus.gov. Retrieved ...
... luteoma MeSH C04.557.475.750.847 - sertoli-leydig cell tumor MeSH C04.557.475.750.847.249 - leydig cell tumor MeSH C04.557. ... luteoma MeSH C04.588.322.455.531 - meigs syndrome MeSH C04.588.322.455.648 - sertoli-leydig cell tumor MeSH C04.588.322.455.765 ...
... luteoma MeSH C13.371.056.630.705.531 - meigs syndrome MeSH C13.371.056.630.705.648 - sertoli-leydig cell tumor MeSH C13.371. ... luteoma MeSH C13.371.820.800.418.685.531 - meigs syndrome MeSH C13.371.820.800.418.685.648 - sertoli-leydig cell tumor MeSH ...
... syndrome Ovotesticular disorder 17β-Hydroxysteroid dehydrogenase III deficiency PCOS Adrenocortical carcinoma Luteoma of ...
... luteoma MeSH C19.344.410.531 - meigs syndrome MeSH C19.344.410.648 - sertoli-leydig cell tumor MeSH C19.344.410.765 - thecoma ... luteoma MeSH C19.391.630.705.531 - meigs syndrome MeSH C19.391.630.705.648 - sertoli-leydig cell tumor MeSH C19.391.630.705.765 ...
... luteinized M8602/0 Sclerosing stromal tumor M8610/0 Luteoma, NOS Luteinoma M8620/1 Granulosa cell tumor, NOS adult type M8620/3 ...
... stromal luteoma, ovarian dermoid cysts, Prader-Willi syndrome, and Alström syndrome. Acanthosis nigricans associated with ...
... luteoma) Increased androgen exposure in utero, not otherwise specified (e.g. androgenic drugs) Developmental Mayer-Rokitansky- ...

No FAQ available that match "luteoma"

No images available that match "luteoma"